This is a phase 3, 32-week, multicenter, single arm, open-label extension study. All enrolled subjects will be administered cinacalcet daily during the treatment period in addition to standard of care treatment which can include therapy with Vitamin D sterols, calcium supplementation, and phosphate binders.